Price $95.55 |
Market Cap
157.01B
|
Sector Health Care |
Div. Growth
-9.90%
|
|
P/E
15.8
|
P/B
43.91
|
P/S
5.27
|
Dividend %
3.90%
|
|
P/CF
36.8
|
P/FCF
27.4
|
Op. Cash Flow
10.5M
|
FCF
3.5
|
|
Op. Margin
34.00%
|
Net Margin
21.50%
|
ROE
119.30%
|
ROI
25.40%
|
|
ROA
9.20%
|
EPS Growth
-15.20%
|
Current Ratio
1.3
|
Debt/Equity
607.30%
|
| Company | Price | P/E | Div. Yield | Market Cap ($Mil) | Rating |
|---|---|---|---|---|---|
| Valeant Pharmaceuticals Intl I (VRX) | $24.72 | - | - | 7.68B | Strong Buy |
| Nature's Sunshine Prod. (NATR) | $8.80 | - | 4.40% | 172.5M | Strong Buy |
| Teva Pharmaceutical Industries (TEVA) | $24.01 | - | 3.90% | 22.05B | Strong Buy |
| NeoGenomics, Inc. (NEO) | $13.92 | - | - | 935.2M | Strong Buy |
| Neurometrix Inc (NURO) | $1.34 | - | - | 10M | Strong Buy |
Please note that all recommendations are based on our model's results and do not represent our personal opinion. The stock Rating process is purely mechanical.
All analysis relies on publicly available financial information. Learn More
